Catheter Precision Q3 revenue up 135% to $226K; net loss down 45% to $2.25M

Catheter Precision, Inc.

Total revenue Q3 2025: $226K, +135% YoY from $96K; nine-month revenue $581K, +114%.
GAAP net loss Q3 2025: $2.25M, 45% reduction from $4.12M in Q3 2024.
Nine-month net loss $11.4M vs $11.0M; non-cash charges $4.2M.
CE Mark approval for LockeT driving international interest; reorders in South Africa and first French VIVO order.
VIVO clinical studies completed in 2025; CEO expects major US and international expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.